Background: Pralatrexate (PDX) is a novel targeted antifolate that is designed to accumulate
preferentially in cancer cells. Pralatrexate selectively enters cells expressing RFC-1, a …

8561 Background: Pralatrexate is a novel targeted antifolate designed to accumulate
preferentially in cancer cells. PROPEL, a pivotal phase 2, non-randomized, open-label …

Pralatrexate is a folate antagonist that selectively enters cells expressing reduced folate
carrier type 1 and competitively inhibits dihydrofolate reductase, leading to interruption of …

Background: Pralatrexate (PDX) is a novel targeted antifolate that is designed to accumulate
preferentially in cancer cells. Pralatrexate has demonstrated activity at a range of doses in …

Abstract Abstract 1675 Poster Board I-701 Background Chemotherapeutic agents may be
associated with early-onset toxicities (eg, bortezomib peripheral neuropathy) or late …

Abstract Abstract 919 Background: Pralatrexate enters cancer cells via the reduced folate
carrier-1 (RFC-1) and is efficiently polyglutamated by folylpolyglutamyl synthetase (FPGS) …

Purpose Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's
lymphoma with no accepted standard of care. This study evaluated the efficacy and …

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin's
lymphomas with poor clinical outcomes. Pralatrexate showed efficacy and safety in recurrent …

Abstract Abstract 3420 Poster Board III-308 Background Stem cell transplant (SCT) may be
offered as a curative approach in patients with chemotherapy-sensitive peripheral T-cell …

Pralatrexate is an antifolate designed to be internalized more rapidly than other traditional
antifolates. Preclinical studies have demonstrated its superiority to methotrexate, and early …